Clinical trial NCT00923169 - References

Renal Cell Carcinoma — Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)

Citation(s)

•   Bandyopadhyay A, Zhu Y, Cibull ML, Bao L, Chen C, Sun L
  A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res. 1999 Oct 1;59(19):5041-6.
•   Blobe GC, Schiemann WP, Lodish HF
  Role of transforming growth factor beta in human disease. N Engl J Med. 2000 May 4;342(18):1350-8. Review.
•   Derynck R, Akhurst RJ, Balmain A
  TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001 Oct;29(2):117-29. Review. Erratum in: Nat Genet 2001 Nov;29(3):351.

A Phase 1 Study of the Safety and Efficacy of GC1008: A Human Anti-Transforming Growth Factor-Beta (TGFBeta) Monoclonal Antibody in Patients With Advanced Renal Cell Carcinoma or Malignant Melanoma

Details for clinical trial NCT00923169